SYSTEMATIC REVIEW article
Front. Med.
Sec. Hematology
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1575914
The Efficacy of New Drug Regimens in Treating Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma Patients: A Systematic Literature Review and Meta-Analysis
Provisionally accepted
- Beijing Chaoyang Hospital, Capital Medical University, Beijing, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
This manuscript presents a systematic literature review and meta-analysis examining the effectiveness of novel drug regimens for newly diagnosed, high-risk cytogenetic multiple myeloma (MM) patients. By reviewing 18 randomized controlled trials, the study highlights advancements in therapies, including next-generation proteasome inhibitors, immunomodulatory drugs, and CD38 antibodies, which show significant improvements in progression-free survival (PFS) and minimal residual disease (MRD) negativity. The findings emphasize the need for tailored strategies for high-risk MM, contributing valuable evidence to enhance clinical decision-making and improve patient outcomes. This analysis aligns with the journal's focus on hematology and oncology research, offering relevant insights for advancing targeted treatment in high-risk cancer populations.
Keywords: Multiple Myeloma, High-risk cytogenetics, Novel Drug Regimens, CD38 antibodies, Progression-free survival, Minimal Residual Disease, Systematic review, Meta-analysis
Received: 13 Feb 2025; Accepted: 22 Apr 2025.
Copyright: © 2025 Zhou and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Wenming Chen, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.